Nutriband Strengthens Patent Protection with New U.S. Patent
Nutriband Strengthens Patent Protection with New U.S. Patent
Patent issuance enhances protection for AVERSA™ transdermal abuse deterrent technology
Nutriband Inc. is proud to announce that the United States Patent and Trademark Office has granted patent number 12,318,492 for its innovative AVERSA™ technology, designed to deter the abuse of transdermal drugs. This represents a significant step forward for Nutriband in expanding its robust intellectual property framework, which now protects its unique technology in a remarkable 46 countries globally.
This newly issued patent is part of Nutriband's ongoing commitment to provide safer pharmaceutical solutions. With this advance, the company aims to maintain its pioneering role in the market while addressing crucial public health concerns related to drug abuse and misuse.
AVERSA™ Technology: A Comprehensive Approach
The AVERSA™ transdermal abuse deterrent technology integrates proprietary aversive agents into transdermal patches. This inventive approach is aimed at preventing the misuse, diversion, and accidental exposure associated with potent drugs, particularly those that have a high abuse potential, such as fentanyl. By incorporating these critical safety measures, Nutriband is not just offering a product but a complete solution geared towards the well-being of patients who genuinely need these pharmaceuticals.
The Market Potential for Aversa™ Fentanyl
Nutriband's flagship product, Aversa™ Fentanyl, is on track to be the first abuse-deterrent fentanyl transdermal system available on the market. Recent market analyses indicate potential peak annual sales ranging from $80 million to $200 million. The commercial viability of this product underscores the urgent need for effective pain management solutions that are both reliable and safe for patients.
International Intellectual Property Portfolio
Nutriband’s AVERSA™ technology is fortified by a comprehensive international intellectual property portfolio. This coverage includes patents granted in several significant markets, including regions like Europe, Japan, Korea, Russia, China, Canada, and Mexico. This vast patent protection not only secures Nutriband’s investment in research and development but also reassures stakeholders of the company’s commitment to innovation within the pharmaceutical landscape.
Commitment to Patient Safety and Accessibility
At Nutriband, patient safety and accessibility are paramount. The AVERSA™ technology ensures that while it safeguards against misuse, it remains available to individuals who need pain management. The balance of maintaining drug availability while preventing potential abuse reflects Nutriband’s dedication to addressing healthcare challenges effectively.
About Nutriband Inc.
Nutriband Inc. continues to pave the way in developing a diverse range of transdermal pharmaceutical products. The company focuses primarily on delivering innovative therapies that incorporate its AVERSA™ technology. By working towards creating transdermal patches that not only help manage pain but also deter abuse, Nutriband demonstrates a responsible approach to pharmaceutical development.
For further inquiries, Nutriband can be reached directly at 407-377-6695 or via email. More detailed information about our products and technologies can be found on our official website.
Frequently Asked Questions
What is Nutriband's recent patent about?
Nutriband's latest patent is for its AVERSA™ transdermal abuse deterrent technology, aimed at preventing the misuse of drugs.
How does AVERSA™ technology work?
AVERSA™ technology uses aversive agents in transdermal patches to minimize the risk of drug abuse and accidental exposure.
What is the estimated market for Aversa™ Fentanyl?
The market potential for Aversa™ Fentanyl is projected to be between $80 million to $200 million annually.
Where is the AVERSA™ technology protected?
AVERSA™ technology is protected by patents in 46 countries, including key markets like the U.S., Europe, and Japan.
How can I contact Nutriband for more information?
You can contact Nutriband at 407-377-6695 or email at info@nutriband.com.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
